Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PTC Gambles On Success With Emflaza; Says Price Revision Is Needed

Executive Summary

Looking to become a therapeutic area leader in DMD, PTC pays $140m up front for Marathon's controversial Emflaza, but the biotech's stock price plummeted, indicating that investors don't share PTC's optimism.


Related Content

Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity
Once More Unto The Breach: PTC's Duchenne Drug Translarna Gets Advisory Cmte.
Marathon's Bad News May Help Industry In Pricing Debate
Few Clouds On High-Priced, Ultra-Orphan Drug Horizon
Emflaza's 505(b)(2) Pathway Review: Rare, But With Precedent
Before Price Controversy, Emflaza Got Easy US Nod With Old But Good Enough Data
Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones
PTC Tumbles On Ataluren Failure In Cystic Fibrosis
Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
‘File Over Protest’ At US FDA: PTC To Pursue Rarely-Used Pathway For DMD Drug


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts